Why referrals and customer mobility, not brand marketing alone, drive new-account growth in life science markets, and how to build the ask into your sales playbook, battle cards, and CRM automation.
When I led commercial efforts at GENEWIZ, we made a deliberate bet: invest heavily in marketing to build the brand. It worked. Awareness climbed, and our name started showing up in more conversations across genomics and molecular biology labs. But when we actually traced where new accounts and orders came from, the story was humbling. Roughly 90% of our new business did not come from the marketing engine we were funding. It came from two sources: referrals from existing customers, and scientists who had used us in one lab, moved to another, and simply ordered from us again.
That number reshaped how I think about growth in life science markets, and it lines up almost exactly with what the best commercial research now shows. In their 2026 Harvard Business Review article on customer referrals, Fred Reichheld, Jamie Cleghorn, and Wojtek Kokoszka make the case that referrals are the most undervalued growth asset most companies own. For life science product and service companies, I’d argue the effect is even stronger and even more poorly managed.
1. What actually drives new-customer growth for a life science company?
| Direct answer
In life science markets, most new accounts come from referrals and customer mobility, including existing customers who recommend you and scientists who carry their vendor preference from one lab to the next, not from brand marketing alone. |
Marketing built our awareness at GENEWIZ, and that mattered because it made the referrals land on fertile ground and shortened the time from recommendation to first order. But awareness did not close the account. A trusted colleague saying “just use them, they’re reliable” closed the account. A scientist who trusted our service in their last role closed the account the day they got a new lab set up.
The lesson is not “stop marketing.” It is that in technical, trust-driven markets, marketing and sales should be built around amplifying referrals rather than treating marketing and sales as substitutes for them.
2. What does the research say about the economics of referred customers?
| Direct answer
Referred customers are disproportionately profitable. Recent Harvard Business Review research found that although only about 20% of new customers are referred, they generate more than 70% of all new-customer profits. |
The HBR analysis, drawn from data on millions of referral-program participants, found that a small core of genuinely enthusiastic customers (what the authors call true promoters, roughly 15% of a customer base) drives the large majority of new-customer profits over a multi-year window. Referred customers cost less to acquire, stay longer, buy more, and go on to refer others, compounding the effect.
The efficiency gap shows up on the income statement. The researchers found that companies leading their category on customer advocacy ran sales, general, and administrative costs at roughly half the level of their laggard peers: near 11% of revenue versus 22%. In B2B specifically, referral advantage is decisive: in the research cited, about 80% of buyers chose the vendor a trusted peer recommended even over a cheaper alternative. In a market where buyers are terrified of a failed experiment, that should surprise no one.
3. Why is the referral effect even stronger in life sciences?
| Direct answer
Life science buyers are unusually mobile and unusually trust-driven, which makes referrals and customer mobility the dominant growth mechanism because a scientist who trusts your reagent, kit, or service carries that preference with them every time they change labs, institutions, or companies. |
Two forces make life sciences different from the consumer and generic B2B markets most referral research studies:
- Extreme buyer mobility. Postdocs move into industry. Scientists move from academia to biotech, from biotech to pharma, from lab A to lab B. Each move creates a warm, high-intent new account because the buyer already knows your product works, yet most companies never even notice it.
- Reproducibility risk. When a bad reagent or a failed run can cost months, peer recommendation is the highest-trust signal a buyer has. A colleague’s “this worked in my hands” outperforms any spec sheet or ad.
At GENEWIZ, the customer-who-changed-jobs pattern was not a rounding error. It was a primary channel. And it was almost entirely unmanaged. We captured it when it happened, but we did nothing systematic to make it happen more often.
4. Why do most life science companies miss this?
| Direct answer
Most companies miss referral-driven growth because they never track it, never systematically ask for it, and let referred accounts get lumped in with generic lead sources, so marketing attribution over-credits paid channels and the real engine stays invisible. |
The HBR authors make a point that will sting for anyone who has run a commercial team: most companies don’t track referrals systematically, so referred customers get credited to whatever campaign happened to touch them last. Paid acquisition looks more effective than it is, and the referral engine, the thing actually producing your best customers, never shows up in a dashboard.
In life sciences the blind spots are specific and fixable:
- There is no required referral-source field on new contacts, so “how did you hear about us” is never captured with discipline.
- Reps ask for referrals when they remember to, which is to say, rarely, and never the same way twice.
- When a known contact appears at a new company, nothing fires. The single most valuable event in the funnel passes silently.
5. How do you build a referral engine into your commercial process?
| Direct answer
Build referrals into growth by making the ask a formal, repeatable step in your sales playbook, battle cards, and CRM automation rather than leaving it to chance or to a rep who remembers to ask once a quarter. |
This is the practical takeaway I wish I had operationalized earlier. Referrals are not a personality trait of your best reps. They are a process, and processes belong in three places:
- Sales playbook: define exactly when and how to ask, including after a successful run or delivery, at onboarding milestones, at renewal, and immediately when a happy contact changes jobs. Make the ask a required stage, not a suggestion.
- Battle cards: give reps referral language mapped to buyer type, including PI, core facility director, biotech scientist, and procurement, so the ask is natural and specific, not a generic “know anyone who needs us?”
- CRM automation: capture referral source on every new contact, tag the referring customer, trigger the ask at defined milestones and, critically, alert the account owner the moment a known contact’s company changes.
| Referrals invisible in your CRM?
PSG Life Sciences is a HubSpot Gold partner that builds referral capture, milestone-triggered ask workflows, and contact-move alerts directly into a life science sales cycle, so your best channel stops being an accident. |
6. What should your CRM capture to operationalize referrals?
| Direct answer
To operationalize referrals, capture the referral source on every new account, link it to the referring contact, and monitor customer job changes so a trusted scientist moving to a new lab automatically becomes a tracked opportunity. |
A referral-aware CRM, in practice a properly configured HubSpot, should capture and act on:
- A required referral-source field on every new contact and deal.
- A link from each referred account back to the referring customer, so you can see who your true promoters are.
- Milestone-triggered workflows that prompt the referral ask automatically after wins, deliveries, and renewals.
- Contact-move detection that flags when a known buyer appears at a new company and routes it to the account owner with an SLA.
- A referral pipeline report the CEO actually reviews, including referral ratio, referral-sourced revenue, and top promoters, alongside marketing metrics.
| Distributor and channel referrals feel like a black box?
PSG helps growth-stage life science companies build the pipeline visibility, shared target lists, and accountability that turn scattered referral activity into a measurable channel. |
Bottom line: where should a life science CEO look for efficient growth?
| Direct answer
The most efficient growth in life sciences comes from a disciplined referral system, not more spend. The companies that win formalize the ask, capture the source, and follow their customers as they move between labs. |
If I could re-run my GENEWIZ playbook, I would not cut the marketing investment. I would point far more of it at delighting the customers already generating 90% of our new business, and I would make asking for referrals as routine as sending a quote. Marketing earns attention. Referrals earn accounts. The companies that grow efficiently in this market are the ones that stop treating that as luck and start treating it as a system.
| Ready to turn referrals into a managed channel?
Talk to PSG Life Sciences about a commercialization assessment, covering referral capture, playbook and battle-card design, CRM automation, and the fractional commercial leadership to run it. |
About the author
Stephen Manobianco leads content and commercialization strategy at PSG Life Sciences, a HubSpot Gold partner and fractional commercialization firm that works exclusively with biotech, life science, and diagnostic product and service companies. He previously led commercial efforts at GENEWIZ, a global genomics services company, where referral- and mobility-driven growth outpaced brand marketing as the primary source of new accounts. PSG builds the sales, marketing, CRM, and referral systems described here as implemented client work, not theory.
Quick-reference FAQ recap
Use this list to populate FAQPage schema. Each question should link to its full answer block above.
What actually drives new-customer growth for a life science company?
In life science markets, most new accounts come from referrals and customer mobility, including existing customers who recommend you and scientists who carry their vendor preference from one lab to the next, not from brand marketing alone.
What does the research say about the economics of referred customers?
Referred customers are disproportionately profitable. Recent Harvard Business Review research found that although only about 20% of new customers are referred, they generate more than 70% of all new-customer profits.
Why is the referral effect even stronger in life sciences?
Life science buyers are unusually mobile and unusually trust-driven, which makes referrals and customer mobility the dominant growth mechanism because a scientist who trusts your product carries that preference every time they change labs, institutions, or companies.
Why do most life science companies miss this?
Most companies miss referral-driven growth because they never track it, never systematically ask for it, and let referred accounts get lumped in with generic lead sources, so attribution over-credits paid channels and the real engine stays invisible.
How do you build a referral engine into your commercial process?
Build referrals into growth by making the ask a formal, repeatable step in your sales playbook, battle cards, and CRM automation rather than leaving it to chance or to a rep who remembers to ask once a quarter.
What should your CRM capture to operationalize referrals?
Capture the referral source on every new account, link it to the referring contact, and monitor customer job changes so a trusted scientist moving to a new lab automatically becomes a tracked opportunity.